Olema Pharmaceuticals Company Insiders

OLMA Stock  USD 4.52  0.11  2.49%   
About 80 percent of Olema Pharmaceuticals' insiders are selling. The analysis of the overall insider sentiment regarding Olema Pharmaceuticals suggests that a fairly large number of insiders are terrified. Olema Pharmaceuticals employs about 101 people. The company is managed by 16 executives with a total tenure of roughly 236 years, averaging almost 14.0 years of service per executive, having 6.31 employees per reported executive.

Insider Sentiment 20

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-01-08Bain Capital Life Sciences InvAcquired 300000 @ 5.76View
2024-12-17G. Walmsley GrahamDisposed 700761 @ 6.75View
2024-12-10Sean BohenDisposed 52328 @ 9.37View
2024-08-01Biocapital Advisors L ParadigmDisposed 2400000 @ 14.91View
2024-07-29Cyrus HarmonDisposed 4066 @ 15.58View
Monitoring Olema Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

Olema Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Olema Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Olema will maintain a workforce of about 100 employees by August 2025.
 
Covid

Olema Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.2744) % which means that it has lost $0.2744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4159) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of July 21, 2025, Return On Tangible Assets is expected to decline to -0.3. The current year's Return On Capital Employed is expected to grow to -0.33. At present, Olema Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 11.8 M, whereas Total Assets are forecasted to decline to about 249.2 M.
As of July 21, 2025, Common Stock Shares Outstanding is expected to decline to about 43.5 M. The current year's Net Loss is expected to grow to about (89.6 M)

Olema Pharmaceuticals Workforce Comparison

Olema Pharmaceuticals is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 686. Olema Pharmaceuticals retains roughly 101 in number of employees claiming about 15% of equities under Health Care industry.

Olema Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Olema Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
2.5
10
4
 6,050,000 
 3,920,000 
2024-12-01
0.6087
14
23
 6,977,643 
 5,725,912 
2024-06-01
1.2222
11
9
 239,460 
 1,249,460 
2024-03-01
0.8889
8
9
 1,785,665 
 639,714 
2023-12-01
0.5385
14
26
 510,737 
 229,074 
2023-09-01
0.8333
5
6
 2,113,618 
 100,000 
2023-06-01
3.0
9
3
 182,160 
 20,000 
2022-03-01
2.2
11
5
 1,909,255 
 26,257 
2021-12-01
0.5333
8
15
 782,845 
 108,740 
2021-09-01
0.35
7
20
 20,753 
 77,506 
2021-06-01
1.2
12
10
 260,467 
 138,028 
2020-12-01
1.0952
46
42
 18,173,646 
 13,574,880 
2020-09-01
5.5
11
2
 3,316,948 
 135,525 

Olema Pharmaceuticals Notable Stakeholders

An Olema Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Olema Pharmaceuticals often face trade-offs trying to please all of them. Olema Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Olema Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sasha CPAVP ControllerProfile
JD MoriartyCorporate SecretaryProfile
Peter KushnerCoFounder FellowProfile
PharmD FaltaosVP PharmacologyProfile
Kinney HornChief OfficerProfile
Cyrus HarmonChief DirectorProfile
Courtney DuganVP CommunicationsProfile
John MoriartyChief VPProfile
Moriarty ESQCorporate SecretaryProfile
Shane MBAChief OfficerProfile
Julie DexterSenior PeopleProfile
Courtney OKonekVice CommunicationsProfile
Naseem MDChief OfficerProfile
David MylesChief OfficerProfile
Geoffrey MogilnerVice CommunicationsProfile
Shawnte JDChief SecretaryProfile

About Olema Pharmaceuticals Management Performance

The success or failure of an entity such as Olema Pharmaceuticals often depends on how effective the management is. Olema Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Olema management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Olema management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.29)(0.30)
Return On Capital Employed(0.35)(0.33)
Return On Assets(0.29)(0.30)
Return On Equity(0.32)(0.30)
Please note, the presentation of Olema Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Olema Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Olema Pharmaceuticals' management manipulating its earnings.

Olema Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Olema Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Olema Pharmaceuticals within its industry.

Olema Pharmaceuticals Manpower Efficiency

Return on Olema Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.3M
Net Loss Per Executive8.1M
Working Capital Per Employee3.9M
Working Capital Per Executive24.8M

Complementary Tools for Olema Stock analysis

When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years